Evidence map›Paper›PMID 21929751›Full record

ArticleJournal of nanobiotechnology2011

Nanoparticle-based delivery of siDCAMKL-1 increases microRNA-144 and inhibits colorectal cancer tumor growth via a Notch-1 dependent mechanism.

Sripathi M Sureban, Randal May, Fadee G Mondalek, Dongfeng Qu, Sivapriya Ponnurangam, Panayotis Pantazis, Shrikant Anant, Rama P Ramanujam, Courtney W Houchen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers.

0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

84 citing papers in PubMed, 154 citations in OpenAlex.

  1. Review
  2. Colorectal Cancer; Novel Approaches in Chimeric Antigen Receptors (CAR) -T cell.International journal of molecular and cellular medicine · 2025
    Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. MicroRNAs, Stem Cells in Bipolar Disorder, and Lithium Therapeutic Approach.International journal of molecular sciences · 2022
    Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

24 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Sripathi M SurebanDepartment of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA.
Randal May
Fadee G Mondalek
Dongfeng Qu
Sivapriya Ponnurangam
Panayotis Pantazis
Shrikant Anant
Rama P Ramanujam
Courtney W Houchen
University of Oklahoma Health Sciences Center · USApplied Decision Science (United States) · USUniversity Hospital and Clinics · US

Funding

Intestinal Stem Cell Consortium Coordinating CenterU01DK085532 · NIDDK · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI NILAND, JOYCE CAROL · 2009 to 2018
$6.5M
Dietary Prevention of CancerR01CA109269 · NCI · WASHINGTON UNIVERSITY · PI ANANT, SHRIKANT · 2005 to 2013
$2.7M
Limited Competition for the Continuation of the Intestinal Stem Cell Consortium Coordinating CenterU24DK085532 · NIDDK · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI NILAND, JOYCE CAROL · 2019 to 2023
$2.3M
Isolation and Characterization of Intestinal Stem Cells Using Novel Markers (RP)U01DK085508 · NIDDK · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI HOUCHEN, COURTNEY WAYNE · 2009 to 2014
$2.0M
INNOVATIVE CELL-BASED URINALYSIS FOR PATIENT ADHERENCER44AT004118 · NCCIH · SWAASTH, INC. · PI RAMANUJAM, RAMA P · 2007 to 2009
$1.5M
RNA Binding Proteins in CancerR01CA135559 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI ANANT, SHRIKANT · 2009 to 2013
$1.5M
PROSTAGLANDIN E2 RECEPTORS IN GASTROINTESTINAL INJURYK08DK002822 · NIDDK · WASHINGTON UNIVERSITY · PI HOUCHEN, COURTNEY WAYNE · 2000 to 2004
$596k
PROSTAGLANDINS AND GASTROINTESTINAL DNA DAMAGER03DK065887 · NIDDK · WASHINGTON UNIVERSITY · PI HOUCHEN, COURTNEY WAYNE · 2004 to 2006
$453k
Pancreatic Stem Cells and CancerR21CA137482 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI HOUCHEN, COURTNEY WAYNE · 2010 to 2011
$346k
NCCIH NIH HHS 3R44AT004118-03S1NCI NIH HHS CA-137482NCI NIH HHS R01 CA109269NCI NIH HHS R01 CA135559NIDDK NIH HHS DK-002822NIDDK NIH HHS DK-065887NIDDK NIH HHS DK-085508NIDDK NIH HHS U01 DK085532NIDDK NIH HHS U24 DK085532
6 · The paper itself

Abstract

backgroundThe development of effective drug delivery systems capable of transporting small interfering RNA (siRNA) has been elusive. We have previously reported that colorectal cancer tumor xenograft growth was arrested following treatment with liposomal preparation of siDCAMKL-1. In this report, we have utilized Nanoparticle (NP) technology to deliver DCAMKL-1 specific siRNA to knockdown potential key cancer regulators. In this study, mRNA/miRNA were analyzed using real-time RT-PCR and protein by western blot/immunohistochemistry. siDCAMKL-1 was encapsulated in Poly(lactide-co-glycolide)-based NPs (NP-siDCAMKL-1); Tumor xenografts were generated in nude mice, treated with NP-siDCAMKL-1 and DAPT (γ-secretase inhibitor) alone and in combination. To measure let-7a and miR-144 expression in vitro, HCT116 cells were transfected with plasmids encoding the firefly luciferase gene with let-7a and miR-144 miRNA binding sites in the 3'UTR.

resultsAdministration of NP-siDCAMKL-1 into HCT116 xenografts resulted in tumor growth arrest, downregulation of proto-oncogene c-Myc and Notch-1 via let-7a and miR-144 miRNA-dependent mechanisms, respectively. A corresponding reduction in let-7a and miR-144 specific luciferase activity was observed in vitro. Moreover, an upregulation of EMT inhibitor miR-200a and downregulation of the EMT-associated transcription factors ZEB1, ZEB2, Snail and Slug were observed in vivo. Lastly, DAPT-mediated inhibition of Notch-1 resulted in HCT116 tumor growth arrest and down regulation of Notch-1 via a miR-144 dependent mechanism.

conclusionsThese findings demonstrate that nanoparticle-based delivery of siRNAs directed at critical targets such as DCAMKL-1 may provide a novel approach to treat cancer through the regulation of endogenous miRNAs.

Indexed as

AnimalsCarcinomaColorectal NeoplasmsDipeptidesDoublecortin-Like KinasesDown-RegulationGene Expression Regulation, NeoplasticHCT116 CellsHumansIntracellular Signaling Peptides and ProteinsMiceMice, NudeMicroRNAsNanoparticlesProtein Serine-Threonine KinasesProto-Oncogene MasDCLK1 protein, humanDipeptidesDoublecortin-Like KinasesIntracellular Signaling Peptides and ProteinsMAS1 protein, humanMicroRNAsMIRN144 microRNA, humanMIRN200 microRNA, humanmirnlet7 microRNA, humanMYC protein, humanN-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl esterNOTCH1 protein, humanProtein Serine-Threonine KinasesProto-Oncogene MasProto-Oncogene Proteins c-mycReceptor, Notch1Transcription Factors

Identifiers

PMID21929751
PMCPMC3200989
OpenAlexW2079830672

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.